NewA start that is aimed at increasing how long people can live a healthy life by genetically planning their cells has increased a series of $ 130 million B, led by Kleiner Perkins.
The new investors Nat Friedman, Daniel Gross and Khosla Ventures have also invested, as were the returned supporters of Founders Fund, Dimension Capital, Elad Gil, Garry Tan, Patrick Collison and others. The fundraise comes two years after increasing the $ 40 million company A.
Four years ago, it was founded by COINBASE CEO Brian Armstrong (depicted above), former GV Blake Byers associate and Jacob Kimmel stem cell professor, Newlimit claims to have made significant progress towards the development of therapies that can be remedied by youth.
Kimmel told TechCrunch that the company has discovered three original drugs that reschedule the liver cells. Newlimit’s laboratory experiments, reported, to show this rejuvenation, can restore the ability of cells to process fat and alcohol.
The company measures its progress as opposed to how the cells from a younger person and an elderly person respond to the substances. An older hepatic cell that has gone through Newlimit’s epigenetic reprogramming behaves more like a newer cell, Kimmel said.
Regardless of the promise of early results, Newlimit is still a few years from the onset of human tests.
Meanwhile, the company wants to continue developing a new anti -aging drug using an AI model and then test the most promising of these medicines produced by machinery in its laboratory. “What the AI model allows us is to run all these experiments in simulation and then follow only the most promising subset,” Kimmel said, adding that the data points from the experiment are then used to re -educate the AI model in a process known as a “workshop”.
TechCrunch event
Berkeley, ca
|
June 5
Book now
Other remarkable biotechnology starts that develop drugs aimed at increasing life include retro bio -sciences, which raised $ 180 million from Openai Sam Altman CEO two years ago and reports that it increases a series of $ 1 billion A and Altos Labs launched with $ 3 billion in 2022 and supported by Jeff Bezos.
